BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 115,011 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 115,011 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $357.87, for a total transaction of $41,158,986.57. Following the completion of the transaction, the chief executive officer directly owned 125,799 shares of the company’s stock, valued at $45,019,688.13. This trade represents a 47.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Wednesday, August 12th, John Oyler sold 54,892 shares of BeOne Medicines stock. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80.
• On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The stock was sold at an average price of $361.90, for a total transaction of $25,661,243.30.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total transaction of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total value of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $359.05 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The company has a market cap of $39.39 billion, a PE ratio of 63.21 and a beta of 0.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The business has a 50-day simple moving average of $301.40 and a two-hundred day simple moving average of $309.13.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ONC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Wells Fargo & Company initiated coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Royal Bank Of Canada reduced their target price on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Finally, Guggenheim boosted their price target on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Buy” and a consensus price target of $402.14.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines and Revolution Medicines announced a partnership covering the clinical development and regional commercialization of oncology therapies. The agreement could expand BeOne’s cancer-treatment portfolio and future commercial opportunities. BeOne and Revolution Medicines partner for oncology therapies
• Positive Sentiment: Revolution Medicines shares rose after the market evaluated the BeOne-funded Phase 3 RAS(ON) collaboration, suggesting investors view the partnership as strategically meaningful for advancing targeted oncology treatments. The indirect benefit to ONC is tied to potential pipeline growth and future commercialization. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The data does not indicate meaningful short-selling pressure, although the reported figures appear unusual and may have limited informational value.
• Negative Sentiment: CEO John Oyler sold 240,810 BeOne Medicines shares across transactions dated August 10–12 for approximately $86.5 million in total. The sales reduced his direct ownership substantially, which can weigh on investor sentiment; however, all three transactions were executed under a pre-arranged Rule 10b5-1 trading plan, reducing the signal that the sales reflect a new negative view of the company. SEC insider transaction filing

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its holdings in shares of BeOne Medicines by 100.6% during the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after purchasing an additional 97,244 shares during the last quarter. Renaissance Technologies LLC acquired a new position in BeOne Medicines during the first quarter valued at $19,438,000. SEB Asset Management AB purchased a new stake in BeOne Medicines in the first quarter valued at $16,653,000. Capital International Sarl boosted its holdings in BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares during the last quarter. Finally, Rokos Capital Management LLP acquired a new stake in BeOne Medicines during the 1st quarter worth about $4,256,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.